logo-loader
Redx Pharma Plc

Issue of Warrants and Change to Lease Agreement

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:36.0pt;text-align:justify;text-indent:-36.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial Bold","serif";}h2{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:72.0pt;text-align:justify;text-indent:-36.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:108.0pt;text-align:justify;text-indent:-36.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h4{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:162.0pt;text-align:justify;text-indent:-54.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:198.0pt;text-align:justify;text-indent:-36.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:9.0pt;margin-left:234.0pt;text-align:justify;text-indent:-36.0pt;line-height:15.0pt;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight:normal;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;} .p{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.p{}p.am{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}p.an{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}h2.af{margin:0cm;margin-bottom:.0001pt;text-indent:0cm;line-height:normal}span.ag{font-size:11.0pt;font-family:"Calibri","sans-serif"}table.aq{margin-left:-5.4pt;border-collapse:collapse;border:none}td.ad{width:130.7pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} h3.ae{font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-indent: 0cm}td.ac{width:123.9pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.ab{width:152.2pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.z{width:130.7pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}h3.aa{margin:0cm;margin-bottom:.0001pt;text-indent:0cm;line-height:normal}td.y{width:123.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.x{width:152.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ar{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}table.as{width:451.5pt; margin-left:-.75pt}td.t{width:339.35pt;padding:.75pt .75pt .75pt .75pt} p.at{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}td.s{width:104.65pt;padding:.75pt .75pt .75pt .75pt}span.q{color:blue} /**/
RNS Number : 3457R
Redx Pharma plc
28 February 2019
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

REDX PHARMA PLC

("Redx" or "the Company")

 

Issue of Warrants and Change to Lease Agreement

 

Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, as previously noted in its 2018 Annual Report, it has successfully completed an agreement with Alderley Park Limited to significantly reduce its accommodation footprint in the Company's Headquarters at Alderley Park, Cheshire.

 

As part of the agreement, on 27 February 2019, a Warrant to acquire 750,000 ordinary shares of 1p each in the share capital of the Company was issued to Alderley Park Limited as follows:

 

The subscription price payable per warrant share on exercise of the warrant is:

 

Price

No. of Shares

Date of Vesting

13.75p

125,000

27 February 2019

20p

125,000

27 February 2019

27p

125,000

27 February 2020

35p

125,000

27 February 2020

42.5p

125,000

27 February 2021

50p

125,000

27 February 2021

 

The Warrant will not become exercisable until the second anniversary of issue.

 

For further information, please contact:

 

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

 

 

 

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

T: +44 20 7894 7000

Phil Davies

 

 

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKODKFBKDFBB

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £10.75 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Redx Pharma gets green light to increase dose in lead cancer...

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

on 20/8/19